Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president sent a letter pushing drug companies to slash prices.

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

The global peptide and anticoagulant drugs market is witnessing significant growth, driven by factors such as the rising prevalence of cardiovascular diseases, technological advancements, and the ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today the pricing of $400.0 million aggregate ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the 'notes”) in a ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced ...

In the second part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, explains how wide regional ...

The Trump administration has imposed a tariff of 39 percent on Swiss goods — drastically higher than the rates for the EU or ...

President Trump wrote to major drug companies, informing them that they had to comply with his “Most Favored Nation” order.

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing reform under the Trump administration, Pfizer CEO Albert Bourla, Ph.D ...